Aktis Oncology Inc. Common stock (AKTS) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Aktis Oncology Inc. Common stock, updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$16.82
+2.25% today
Market cap
$915M
Overall quality
52/100
Kronos AI 30-day
+47.0%
8 of 8 simulated paths end higher
Aktis Oncology Inc. Common stock (AKTS) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $915M. It trades at $16.82, up 2.25% today. Its overall quality score is 52 out of 100, ranked against the whole US market. 6 analysts' average target of $35.80 implies +112.8% from today's price. Kronos AI's 30-day forecast is +47.0% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $35.80 |
| Low – high | $33.00 – $40.00 |
| Analysts | 6 |
| Upside to average | +112.8% |
Kronos AI 30-day forecast
| Expected close | $24.19 (+47.0%) |
| Likely range | +21.0% … +54.5% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 30 |
| Solvency | 68 |
| Growth | 59 |
| Overall | 52 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.